伏诺拉生治疗胃食管反流病的研究进展  

Vonoprazan for treatment of gastroesophageal reflux disease:Research advances

作　　者：许文涛 许向波 任天舒 祁兴顺 Wen-Tao Xu;Xiang-Bo Xu;Tian-Shu Ren;Xing-Shun Qi(Department of Gastroenterology,General Hospital of Northern Theater Command,Shenyang 110840,Liaoning Province,China;Postgraduate College,Shenyang Pharmaceutical University,Shenyang 110016,Liaoning Province,China;Department of Pharmacy,General Hospital of Northern Theater Command,Shenyang 110840,Liaoning Province,China)

机构地区：[1]北部战区总医院消化内科,辽宁省沈阳市110840 [2]沈阳药科大学研究生院,辽宁省沈阳市110016 [3]北部战区总医院药剂科,辽宁省沈阳市110840

出　　处：《世界华人消化杂志》2021年第21期1248-1253,共6页World Chinese Journal of Digestology

摘　　要：胃食管反流病是常见的消化道疾病,药物是主要的治疗手段.质子泵抑制剂(proton pump inhibitors,PPIs)是治疗胃食管反流病(gastroesophageal reflux disease,GERD)的经典药物,但并未完全满足临床需求.伏诺拉生(vonoprazan)是一种新型抑制胃酸分泌药物,可用于治疗GERD.本文旨在全面回顾有关伏诺拉生治疗GERD的临床疗效和安全性证据,以指导临床实践.Gastroesophageal reflux disease is a common gastrointestinal disease that can be effectively treated by drugs alone.Proton pump inhibitors are the currently mainstay drugs for the treatment of gastroesophageal reflux disease,but are insufficiently effective.Vonoprazan,which is a new type of drug that inhibits gastric acid secretion,has been employed for the management of gastroesophageal reflux disease.In this article,we comprehensively review the current evidence regarding clinical efficacy and safety of vonoprazan for the treatment of gastroesophageal reflux disease to guide the clinical decision.

关 键 词：伏诺拉生 质子泵抑制剂 胃食管反流病 

分 类 号：R571[医药卫生—消化系统]